



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

PAP-2d siRNA (m): sc-152009

BACKGROUND

PAP-2d (phosphatidic acid phosphatase 2d), also known as LPPR5 (lipid phosphate phosphatase-related protein type 5) or PRG-5 (plasticity-related gene 5 protein), is a 321 amino acid multi-pass membrane protein that belongs to the phosphatidic acid phosphatase (PAP) related phosphoesterase family and exists as two alternatively spliced isoforms. Isoform 1 is expressed in brain, lung, kidney and colon, while isoform 2 is expressed in placenta, skeletal muscle and kidney. The gene that encodes PAP-2d consists of around 114,788 bases and maps to human chromosome 1p21.3. Comprising nearly 8% of the human genome, chromosome 1 spans 260 million base pairs, contains over 3,000 genes and houses a large number of disease-associated genes, including those that are involved in familial adenomatous polyposis, Stickler syndrome, Parkinson's disease, Gaucher disease, schizophrenia and Usher syndrome.

REFERENCES

1. Eudy, J.D., et al. 1998. Isolation of a gene encoding a novel member of the nuclear receptor superfamily from the critical region of Usher syndrome type IIa at 1q41. *Genomics* 50: 382-384.
2. Lau, E.K., et al. 1999. Two novel polymorphic sequences in the glucocerebrosidase gene region enhance mutational screening and founder effect studies of patients with Gaucher disease. *Hum. Genet.* 104: 293-300.
3. Tayebi, N., et al. 2001. Gaucher disease and parkinsonism: a phenotypic and genotypic characterization. *Mol. Genet. Metab.* 73: 313-321.
4. Plasilova, M., et al. 2004. Exclusion of an extracolonic disease modifier locus on chromosome 1p33-36 in a large Swiss familial adenomatous polyposis kindred. *Eur. J. Hum. Genet.* 12: 365-371.
5. Sun, L., et al. 2005. Cloning and characterization of a novel human phosphatidic acid phosphatase type 2, PAP2d, with two different transcripts PAP2d_v1 and PAP2d_v2. *Mol. Cell. Biochem.* 272: 91-96.
6. Betarbet, R., et al. 2008. Fas-associated factor 1 and Parkinson's disease. *Neurobiol. Dis.* 31: 309-315.
7. Holliday, E.G., et al. 2009. Strong evidence for a novel schizophrenia risk locus on chromosome 1p31.1 in homogeneous pedigrees from Tamil Nadu, India. *Am. J. Psychiatry* 166: 206-215.
8. Yokoi, T., et al. 2009. Analysis of the vitreous membrane in a case of type 1 Stickler syndrome. *Graefes Arch. Clin. Exp. Ophthalmol.* 247: 715-718.
9. Broggin, T., et al. 2010. Plasticity-related gene 5 (PRG5) induces filopodia and neurite growth and impedes lysophosphatidic acid- and nogo-A-mediated axonal retraction. *Mol. Biol. Cell* 21: 521-537.

CHROMOSOMAL LOCATION

Genetic locus: 4833424015Rik (mouse) mapping to 3 G1.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.

PRODUCT

PAP-2d siRNA (m) is a pool of 3 target-specific 19-25 nt siRNAs designed to knock down gene expression. Each vial contains 3.3 nmol of lyophilized siRNA, sufficient for a 10 μ M solution once resuspended using protocol below. Suitable for 50-100 transfections. Also see PAP-2d shRNA Plasmid (m): sc-152009-SH and PAP-2d shRNA (m) Lentiviral Particles: sc-152009-V as alternate gene silencing products.

For independent verification of PAP-2d (m) gene silencing results, we also provide the individual siRNA duplex components. Each is available as 3.3 nmol of lyophilized siRNA. These include: sc-152009A, sc-152009B and sc-152009C.

STORAGE AND RESUSPENSION

Store lyophilized siRNA duplex at -20° C with desiccant. Stable for at least one year from the date of shipment. Once resuspended, store at -20° C, avoid contact with RNAses and repeated freeze thaw cycles.

Resuspend lyophilized siRNA duplex in 330 μ l of the RNase-free water provided. Resuspension of the siRNA duplex in 330 μ l of RNase-free water makes a 10 μ M solution in a 10 μ M Tris-HCl, pH 8.0, 20 mM NaCl, 1 mM EDTA buffered solution.

APPLICATIONS

PAP-2d siRNA (m) is recommended for the inhibition of PAP-2d expression in mouse cells.

SUPPORT REAGENTS

For optimal siRNA transfection efficiency, Santa Cruz Biotechnology's siRNA Transfection Reagent: sc-29528 (0.3 ml), siRNA Transfection Medium: sc-36868 (20 ml) and siRNA Dilution Buffer: sc-29527 (1.5 ml) are recommended. Control siRNAs or Fluorescein Conjugated Control siRNAs are available as 10 μ M in 66 μ l. Each contain a scrambled sequence that will not lead to the specific degradation of any known cellular mRNA. Fluorescein Conjugated Control siRNAs include: sc-36869, sc-44239, sc-44240 and sc-44241. Control siRNAs include: sc-37007, sc-44230, sc-44231, sc-44232, sc-44233, sc-44234, sc-44235, sc-44236, sc-44237 and sc-44238.

RT-PCR REAGENTS

Semi-quantitative RT-PCR may be performed to monitor PAP-2d gene expression knockdown using RT-PCR Primer: PAP-2d (m)-PR: sc-152009-PR (20 μ l). Annealing temperature for the primers should be 55-60° C and the extension temperature should be 68-72° C.

RESEARCH USE

For research use only, not for use in diagnostic procedures.